A real-world study found that sustained Zepbound (tirzepatide) use in adults over age 55 with obesity was associated with lower healthcare costs, alongside reduced hospital admissions and emergency department visits. The retrospective observational analysis used Komodo’s Healthcare Map with de-identified claims data from more than 330 million people. The study estimated that by six months, costs were up to 15% lower (as much as $181 per patient per month) versus untreated controls, with differences widening by 12 months to up to $607 per patient per month. The analysis also reported numerically higher routine outpatient and office visit rates, consistent with increased engagement in preventive care. Cost savings were compared against program-related treatment expense for the Medicare GLP-1 Bridge structure, with estimated savings nearly covering costs by six months and exceeding them by 12 months in the primary and reweighted approaches.